These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32142368)

  • 1. Lack of Standardization in the Processing and Reporting of Post-Neoadjuvant Breast Cancer Specimens.
    Han R; Regpala S; Slodkowska E; Nofech-Mozes S; Hanna W; Parra-Herran C; Lu FI
    Arch Pathol Lab Med; 2020 Oct; 144(10):1262-1270. PubMed ID: 32142368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathologic reporting practices for breast cancer specimens after neoadjuvant chemotherapy-a survey of pathologists in academic institutions across the United States.
    Lanjewar S; Patil P; Fineberg S
    Mod Pathol; 2020 Jan; 33(1):91-98. PubMed ID: 31383962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Processing and Reporting of Breast Specimens in the Neoadjuvant Setting.
    Bossuyt V
    Surg Pathol Clin; 2018 Mar; 11(1):213-230. PubMed ID: 29413658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group.
    Provenzano E; Bossuyt V; Viale G; Cameron D; Badve S; Denkert C; MacGrogan G; Penault-Llorca F; Boughey J; Curigliano G; Dixon JM; Esserman L; Fastner G; Kuehn T; Peintinger F; von Minckwitz G; White J; Yang W; Symmans WF;
    Mod Pathol; 2015 Sep; 28(9):1185-201. PubMed ID: 26205180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast Specimen Processing and Reporting With an Emphasis on Margin Evaluation: A College of American Pathologists Survey of 866 Laboratories.
    Guidi AJ; Tworek JA; Mais DD; Souers RJ; Blond BJ; Brown RW
    Arch Pathol Lab Med; 2018 Apr; 142(4):496-506. PubMed ID: 29328775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [GEFPICS' guidelines for management of breast cancer tissue samples in the neoadjuvant setting].
    Maran-Gonzalez A; Franchet C; Duprez-Paumier R; Antoine M; Barlier C; Becette V; Berghian A; Blanc-Fournier C; Brabencova E; Charafe-Jauffret E; Chenard MP; Dauplat MM; Delrée P; Fleury C; Garbar C; Ghnassia JP; Haudebourg J; MacGrogan G; Mathieu MC; Michenet P; Penault-Llorca F; Poulet B; Robin Y; Roger P; Russ E; Treilleux I; Valent A; Verriele V; Vincent-Salomon A; Arnould L; Lacroix-Triki M;
    Ann Pathol; 2019 Dec; 39(6):383-398. PubMed ID: 31257035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How do we measure a residual tumor size in histopathology (the gold standard) after neoadjuvant chemotherapy?
    Apple SK; Suthar F
    Breast; 2006 Jun; 15(3):370-6. PubMed ID: 16185870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standardizing Pathologic Evaluation of Breast Carcinoma After Neoadjuvant Chemotherapy.
    Sahoo S; Krings G; Chen YY; Carter JM; Chen B; Guo H; Hibshoosh H; Reisenbichler E; Fan F; Wei S; Khazai L; Balassanian R; Klein ME; Shad S; Venters SJ; Borowsky AD; Symmans WF; Ocal IT
    Arch Pathol Lab Med; 2022 May; 147(5):591-603. PubMed ID: 35976643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ever-evolving role of pathologists in the management of breast cancer with neoadjuvant treatment: recommendations based on the Spanish clinical experience.
    Burgués O; López-García MÁ; Pérez-Míes B; Santiago P; Vieites B; García JF; Peg V
    Clin Transl Oncol; 2018 Mar; 20(3):382-391. PubMed ID: 28795336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response.
    Rajan R; Poniecka A; Smith TL; Yang Y; Frye D; Pusztai L; Fiterman DJ; Gal-Gombos E; Whitman G; Rouzier R; Green M; Kuerer H; Buzdar AU; Hortobagyi GN; Symmans WF
    Cancer; 2004 Apr; 100(7):1365-73. PubMed ID: 15042669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Standardizing of Pathology in Patients Receiving Neoadjuvant Chemotherapy.
    Bossuyt V; Symmans WF
    Ann Surg Oncol; 2016 Oct; 23(10):3153-61. PubMed ID: 27380637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Perfect Pathology Report After Neoadjuvant Therapy.
    Marchiò C; Maletta F; Annaratone L; Sapino A
    J Natl Cancer Inst Monogr; 2015 May; 2015(51):47-50. PubMed ID: 26063886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting.
    Sahoo S; Lester SC
    Arch Pathol Lab Med; 2009 Apr; 133(4):633-42. PubMed ID: 19391665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mammographically directed breast biopsies: a College of American Pathologists Q-Probes study of clinical physician expectations and of specimen handling and reporting characteristics in 434 institutions.
    Nakhleh RE; Jones B; Zarbo RJ
    Arch Pathol Lab Med; 1997 Jan; 121(1):11-8. PubMed ID: 9111087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast specimen handling and reporting in the post-neoadjuvant setting: challenges and advances.
    Mrkonjic M; Berman HK; Done SJ; Youngson B; Mulligan AM
    J Clin Pathol; 2019 Feb; 72(2):120-132. PubMed ID: 30670564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome.
    Carey LA; Metzger R; Dees EC; Collichio F; Sartor CI; Ollila DW; Klauber-DeMore N; Halle J; Sawyer L; Moore DT; Graham ML
    J Natl Cancer Inst; 2005 Aug; 97(15):1137-42. PubMed ID: 16077072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathologic response and long-term follow-up in breast cancer patients treated with neoadjuvant chemotherapy: a comparison between classifications and their practical application.
    Corben AD; Abi-Raad R; Popa I; Teo CH; Macklin EA; Koerner FC; Taghian AG; Brachtel EF
    Arch Pathol Lab Med; 2013 Aug; 137(8):1074-82. PubMed ID: 23899063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
    Campbell JI; Yau C; Krass P; Moore D; Carey LA; Au A; Chhieng D; Giri D; Livasy C; Mies C; Rabban J; Sarode VR; Singh B; Esserman L; Chen YY
    Breast Cancer Res Treat; 2017 Aug; 165(1):181-191. PubMed ID: 28577078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current gross examination and reporting patterns of post-neoadjuvant chemotherapy cystectomy specimens: Is it time for a standardized approach?
    Saunders KE; Gerken N; Khani F; Williamson SR; Wobker SE
    Am J Clin Pathol; 2024 May; 161(5):483-489. PubMed ID: 38240078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathologic evaluation of specimens after neoadjuvant chemotherapy in breast cancer: Current recommendations and challenges.
    See SHC; Siziopikou KP
    Pathol Res Pract; 2022 Feb; 230():153753. PubMed ID: 34990870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.